Liebman H A, Chediak J, Fink K I, Galvez A G, Shah P C, Sham R L
University of Southern California School of Medicine, Division of Hematology, Los Angeles, California 90033, USA.
Am J Hematol. 2000 Mar;63(3):109-13. doi: 10.1002/(sici)1096-8652(200003)63:3<109::aid-ajh1>3.0.co;2-o.
Eight patients with inhibitors to factor VIII (4 hemophilia A and 4 nonhemophilic) were treated with recombinant activated factor VII (rFVIIa) to control severe abdominal bleeding. The recombinant factor was supplied under an open-label, emergency-use program to patients previously unresponsive to one or more alternative therapies. Therapy with rFVIIa was administered for nine separate bleeding events; one patient was treated for two separate bleeding episodes. Patients were treated for an average of 9 days and received a mean total dose of 5.2 mg of rFVIIa for control of bleeding. Treatment was considered successful and hemostasis adequate in 7 of the 9 episodes (78%). Treatment with rFVIIa was partially successful in one other episode. Four patients in this series experienced serious adverse events; all the adverse events were considered unrelated to rFVIIa therapy. The results of this limited series indicate that rFVIIa is an effective means of managing life-threatening abdominal bleeding in individuals with hemophilia or acquired antibodies to factor VIII.
八名患有抗凝血因子VIII抑制剂的患者（4例甲型血友病患者和4例非血友病患者）接受了重组活化凝血因子VII（rFVIIa）治疗，以控制严重的腹部出血。重组因子是在开放标签的紧急使用计划下提供给先前对一种或多种替代疗法无反应的患者的。rFVIIa治疗用于九个不同的出血事件；一名患者接受了两次不同的出血发作治疗。患者平均接受治疗9天，为控制出血平均共接受5.2毫克rFVIIa治疗。9次发作中有7次（78%）治疗被认为成功且止血充分。在另一例发作中，rFVIIa治疗部分成功。该系列中的四名患者发生了严重不良事件；所有不良事件均被认为与rFVIIa治疗无关。这个有限系列的结果表明，rFVIIa是治疗血友病或获得性抗凝血因子VIII抗体个体危及生命的腹部出血的有效手段。
